Biotech | March 16, 2026
There are limited treatment options available for patients living with non-diabetic CKD, and the unmet need is high for new treatments to delay kidney disease progression and reduce cardiovascular risk
Cadila Pharmaceuticals’ journey has been marked by several milestones, including the development of indigenous formulations, expansion into global markets, and the creation of robust manufacturing and R&D capabilities
The facility will manufacture the critical antibiotic intermediate Amino Cephalosporanic Acid (ACA), a key component in the production of cephalosporin antibiotics
Lilly has long voiced concerns over mass-compounded knockoffs of its tirzepatide medicines, Mounjaro and Zepbound
Neupharma gains exclusive rights to develop and commercialize corticorelin for peritumoral brain edema
The trial’s primary goal is to evaluate vipoglanstat’s effect on endometriosis-related pain during non-menstrual days
The move comes as China rapidly expands its capabilities in the pharmaceutical sector, particularly in licensing and drug development
The endorsement follows overwhelming support for the share swap preceding the merger,
The conflict is also triggering a widening public health emergency
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
